PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2016 November 1; 7(44): 71620–71634.
Published online 2016 September 27. doi:  10.18632/oncotarget.12287
PMCID: PMC5342106

Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data

Abstract

Triple negative breast cancers (TNBCs) are highly heterogeneous and aggressive without targeted treatment. Here, we aim to systematically dissect TNBCs from a prognosis point of view by building a subnetwork atlas for TNBC prognosis through integrating multi-dimensional cancer genomics data from The Cancer Genome Atlas (TCGA) project and the interactome data from three different interaction networks. The subnetworks are represented as the protein-protein interaction modules perturbed by multiple genetic and epigenetic interacting mechanisms contributing to patient survival. Predictive power of these subnetwork-derived prognostic models is evaluated using Monte Carlo cross-validation and the concordance index (C-index). We uncover subnetwork biomarkers of low oncogenic GTPase activity, low ubiquitin/proteasome degradation, effective protection from oxidative damage, and tightly immune response are linked to better prognosis. Such a systematic approach to integrate massive amount of cancer genomics data into clinical practice for TNBC prognosis can effectively dissect the molecular mechanisms underlying TNBC patient outcomes and provide potential opportunities to optimize treatment and develop therapeutics.

Keywords: triple-negative breast cancer, landmark for cancer prognosis, GTPase, ubiquitination, oxidative damage

INTRODUCTION

TNBCs refer to certain breast cancers negative of estrogen receptor (EsR) and progesterone receptor (PgR) expression, as well as Her-2/Neu receptor overexpression [1]. They are significantly associated with younger age, African American and Hispanic ethnicities, more aggressiveness, higher distant recurrence, and poorer survival than other breast cancers [2, 3]. Traditional hormone-based therapy (i.e. tamoxifen to target EsR positive cells), and antibody-based therapy (i.e. trastuzumab to target Her2/Neu positive breast cancers) are not effective when treating TNBCs [4]. In the past several years, multiple clinical trials have focused on TNBCs [57], but all failed, despite a few ongoing clinical trials show some promising results [1]. Meanwhile, multiple studies have focused on finding prognostic and/or therapeutic markers. Some common markers have been identified, such as basal cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) [8, 9]. Recently, microRNAs and lncRNAs have become emerging targets to predict cancer prognosis and classify patients for clinical treatment [1013]. However, chemotherapy still remains as the only clinical option for TNBCs [4].

It is well known that cancer is a complex disease because of combined effects of multiple genetic and epigenetic changes and subsequent dys-regulation of critical signaling pathways [14]. The heterogeneity of TNBCs further exacerbates the problem to identify prognostic and/or therapeutic markers [1]. Pioneering molecular portraits of human breast cancer have provided us invaluable information about the link between gene expression pattern and phenotypic diversity [15]. Similarly, pioneering prognosis work for breast cancer patients mainly used gene expression signatures [16, 17] combined with various analytic approaches such as meta-analysis, functional enrichment analysis, and transcriptional network analysis [18]. Thanks to the recent advances in next-generation sequencing technology, we are able to acquire multi-dimensional genomic data with clinical information from a large number of patient samples from Cancer Genome Atlas (TCGA) including breast cancer [19], and dissect cancers beyond the traditional clinical variables (i.e. age and tumor stage) by incorporating multi-layered data to represent genomic activity at different levels, such as gene expression profiles, gene copy number variants (CNVs), miRNA expression, DNA methylation states and molecular interaction networks. Such integrated analyses using multi-layered molecular information have been performed to help understand cancer outcomes [20, 21].

Here, we seek to identify prognostic markers using a network-based approach through integrative analysis of TCGA cancer genomics data due to the hypothesis that multiple genetic and epigenetic events together lead to a complex TNBC outcome. In this work, we proposed a systematic methodology to predict cancer prognosis: (1) Score each gene based on the synthetic effect of different molecular features (mRNA expression, CNV, and DNA methylation) on patient overall survival, (2) Identify novel subnetwork signatures correlated with patient survival, (3) Assess the prognostic power of the subnetwork signatures, and (4) Evaluate the utility of these subnetwork-derived models in TNBC prognosis through functional enrichment analysis, tumor stratification, and independent validation. We find subnetworks related to low oncogenic GTPase activity, low ubiquitin/proteasome degradation, effective protection from oxidative damage, low PIK3A activity, and tightly immune response are linked to better prognosis. Several biosynthesis and metabolism related subnetworks have also been identified. We expect that such a systems biology/precision medicine approach to integrate cancer genomics and interactome data can be useful to understand mechanisms underlying TNBC prognosis and benefit clinical TNBC management.

RESULTS

Discovery of network-based prognostic biomarkers

We extracted the molecular features (including mRNA, CNV, and DNA methylation), clinical variables (i.e. age, tumor stage, and grade), and overall survival information of 119 TNBC patients and 583 non-TNBC patients in TCGA. TNBC and non-TNBC patients were separated according to the EsR, PsR, and HER2 status (Table (Table1).1). Mutation was not included because it happens rarely across the whole genome despite some common mutations (i.e. TP53), which can be considered as a clinical variable and left as an indicator for predication evaluation or subtyping. miRNA was not included neither because of the insufficient samples left for analysis.

Table 1
Summary of the three primary molecular features derived from specimens of BRCA in TCGA by high throughput analysis

Considering the fact that multiple genes and multiple levels of regulation may function together to generate the complex cancer outcome, we adopted a network-based approach to generate multi-dimensional subnetwork-based predictors for the prognosis of TNBC (Figure (Figure1).1). First, we did a pre-selection step using a multivariate Cox proportional hazards model to estimate the effect of different molecular features on patient overall survival time. In total, we selected 1,650 features as hazard factors, including 383 mRNA expression changes, 623 promoter DNA methylation changes, and CNV of 644 genes, which mapped to total 1,487 survival-related genes (p < 0.05 as the significance cutoff from the likelihood ratio test). Next, we derived a score (heat) for each of the genes through the Equation (1) as the input into HotNet2 [22, 23], which uses a heat diffusion process and a statistical test based algorithm to discover subnetwork signatures in three PPI networks (HINT [24]+ HI-2012 [25], iRefIndex [26], and MultiNet [27]). Totally, 41 altered subnetworks with > = 4 nodes were detected. Furthermore, we assessed the predictive power of these subnetwork-based molecular signatures using the median C-index calculated from the Monte Carlo cross-validation (MATERIALS AND METHODS). The nonparametric C-index is scaled such that a C-index of 1 indicates perfect prediction accuracy, whereas a C-index of 0.5 is equal to random guess. We identified 39 out of the 41 subnetworks with a C-index > 0.5 and multiple subnetworks were detected in more than one PPI network (i.e. inthint1/iref3/multinet2, iref2/multinet1, iref4/multinet6) (Figure (Figure2).2). These subnetworks were numbered from 1 to N according to the predictive power in descending order (Figure (Figure22 and Supplementary Tables S1S3). To further understand how these subnetwork biomarkers may be related to patient survival, we investigated individual gene using NCBI Entrez Gene [28] and literature search and performed functional enrichment analysis based on the known pathways or ontologies using Enrichr [29]. Such a thorough analysis identified several pathways known to be involved in TNBC such as iref4/multinet6, which contain BRCA1 interacting partners and PIK3A signaling pathway [30]. Several metabolism-related subnetworks have also been identified, such as multinet3 and multinet4/8/9/12. Most importantly, we found quite large amount of a subnetworks related to GTPase, endoplasmic reticulum (ER)-Golgi-cell surface trafficking, ubiquitin/proteasome system, and complement system (Figure (Figure33 and S1 text).

Figure 1
An overview of the methodology
Figure 2
Predictive power ranking of the survival related subnetwork biomarkers
Figure 3
Biological insights of the top/shared prognostic subnetwork biomarkers

Furthermore, we calculated P-values based on the comparison of the median C-index values of the original survival data with the distributions of the median C-indexes of the 100 permuted survival data to test if the models were statistically significant (C-index > 0.5, survival-data permutation test p < 0.05 as filter criteria). Finally, we determined 1 subnetwork in HINT+HI2012 (inthint1), 5 in iRefIndex (iref1 ~ iref4, iref6), 6 in MultiNet (multinet1 ~ multinet6) as candidate prognostic biomarkers significantly associated with patient overall survival, which were labeled with a star in Figure Figure22 and plotted in detail in Figure Figure3A3A.

Independent validation

Given the limited availability of suitable independent data providing the highly integrated and multi-dimensional genomic data, we validated our subnetwork biomarkers using the most common and accessible gene expression data only. For each subnetwork biomarker, as previously described [31], a risk score model was developed as a linear combination of the mRNA expression levels of the genes in the subnetwork and the estimated regression coefficients in the multivariate Cox regression analysis as the weight (MATERIALS AND METHODS). We were able to calculate a subnetwork-based risk score (referred to as “snRS”) for each patient in the 119 TCGA TNBC samples and classified them into high-risk or low-risk group using the median risk score as the cutoff, The same score model obtained from the discovery series was used to calculate the snRS for each patient from four independent data sets (GSE1456, GSE31448, GSE16446 and GSE25066) (Table (Table2).2). We found that the snRSs for 10 subnetwork biomarkers were significantly associated with survival in at least one data set tested and most of the top/shared subnetworks described above were validated (Figure (Figure4).4). Particularly, iref2/multinet1, the subnetwork containing RAB protein and its inhibitor CHML was significant in TCGA (log-rank p = 0.0152), GSE1456 (log-rank p = 0.025), and GSE25066 (log-rank p = 0.033). Such analysis validated that our subnetwork biomarkers were well predictive of TNBC survival.

Table 2
Four breast cancer data sets used for independent validation
Figure 4
Independent validation of the subnetwork biomarkers obtained from TCGA

Prognostic value of the subnetwork-based biomarkers to assess TNBC clinical outcome

To assess whether the prognostic values of the subnetwork signatures are independent of conventional clinical factors of TNBC patients, we performed the univariate and multivariate analysis using the snRS of iref2 (or multinet6) or other clinical factors as explanatory variables. The result indicated that the snRS maintained an independent correlation with overall survival after adjusting for conventional clinical factors, including age, stage, number of lymph nodes, tumor weight, as shown in Table Table3.3. For example, iref2, as an independent risk factor, was significantly associated with overall survival of TNBC patients (HR = 4.2384, 95% CI: 2.19255–8.193, p = 1.75E-05). Taken together, these analyses demonstrated the added value of the subnetwork-based biomarkers in a prognostic setting.

Table 3
Univariate and multivariate Cox regression analysis of overall survival in TCGA TNBC dataset

Comparison with molecular feature-based prognostic predictor

To test our hypothesis that incorporating prior knowledge of cellular protein-protein interactions could enhance the biological insight and predict utility of TCGA genomic data, we compared our network-based method with the molecular feature-based method. To assess the predictive power of individual molecular data type or the combined profiling of multiple types of molecular data, we used the same procedure as described in Yuan's study (which could be accessed in Synapse (doi:10.7303/syn1710282) [20] (MATERIALS AND METHODS). We observed that mRNA data only could hardly predict TNBC patient survival (C-Index = 0.44), while DNA methylation data and combined molecular data (mRNA + CNV + DNA methylation) have improved prognostic power (C-Index = 0.52 and 0.51 respectively). In contrast, mRNA is the best data type to predict the survival of non-TNBC (C-Index = 0.59) (Figure (Figure5).5). Such analysis indicated that each molecular data type contributed to TNBC prognosis and combining all types of data could lead to better but limited prognostic predictive power. However, when using our subnetwork-based biomarkers, the predictive power was significantly improved (median C-index = 0.7573 for iref1 vs median C-index = 0.51 for combined molecular-based model, one-sided Wilcoxon signed rank test, p < 0.0019). Therefore, our subnetwork biomarkers based on biologically related genes and interactions are more meaningful than molecular feature based biomarkers merely selected by LASSO throughout the genome.

Figure 5
Comparison of the prognostic power among individual and combined molecular data types

Application of the network-based biomarkers for survival oriented TNBC stratification

We further stratified the 119 TNBC patients into high-risk and low-risk groups (HR = 2.482; 95% CI, 0.9973 to 6.176; p = 0.0507) via non-negative matrix factorization (NMF) based on the similarity of their molecular profiles, which included 444 molecular features (CNV: 157, methylation: 106, mRNA: 181) derived from the 39 subnetwork models with a C-index > 0.5 (MATERIALS AND METHODS). We found that cluster 2 has better prognosis than cluster 1 on overall survival and recurrence-free survival (RFS) (Figure 6A and 6B). Based on the hierarchical clustering results, we found three most different molecular clusters between the high-risk and low-risk groups: a DNA methylation cluster with hyper-methylation in poor survival group enriched with genes in Legionellosis (p = 2.9×10e-5) and a hypo-methylation cluster enriched of genes in Metabolism (p = 0.04), as well as an mRNA cluster with higher expression level of the genes enriched in complement and coagulation cascades (p = 8.836e-12) in good survival group. Furthermore, we categorized our 116 TNBC samples to the six subtypes using a web-based subtyping tool (http://cbc.mc.vanderbilt.edu/tnbc/) based on a comprehensive study performed by Lehmann et al., which categorized TNBC to six subtypes from 587 TNBC cases based on gene expression profile [32]. Three samples were filtered out based on their sample checking criteria. Interestingly, though Lehmann subtypes were not determined by prognosis (log-rank p = 0.2512), our method categorized that IM subtype mainly belonged to cluster 2 while BL1 and M subtypes belong to cluster 1, with better or worse prognosis respectively (Figure (Figure6C6C).

Figure 6
Survival related tumor stratification

DISCUSSION

In this study, we developed a network based method combining multidimensional genetic and epigenetic information as well as clinical data to dissect the mechanisms underlying overall survival of TNBC patients. We identified subnetwork signatures containing important genes, interacting partners, and regulating patterns linked to patient overall survival. We found that low oncogenic GTPase activity, low ubiquitin/proteasome degradation, effective protection from oxidative damage, and tightly immune response were linked to better prognosis. We also confirmed low PIK3A activity and revealed certain metabolism features related to better prognosis. To achieve a prognosis-favor environment, ER and Golgi are of particular importance (Figure (Figure3B3B).

Here, we particularly would like to discuss the biological insights from two subnetworks while more literature based and functional enrichment-based analyses can be found in supporting information (S1 text).

inthint1/iref3/multinet2

UBA5 (ubiquitin like modifier activating enzyme 5) and UFM1 (ubiquitin-fold modifier 1) were identified as a novel protein-conjugating system, knockdown or depletion of which could lead to unfolded protein response (UPR), ER stress, and inhibited vesicle trafficking [33, 34]. Knockdown of UBA5 has been shown to inhibit breast cancer cell growth [35], implying the low activity of this ubiquitination system is beneficial for patient survival. APEH (acylaminoacyl-peptide hydrolase) plays an important role in destroying oxidatively damaged proteins in living cells [36] and deletion of APEH locus have been found in small cell lung carcinoma [37] and renal cell carcinoma [38]. As a mammalian lectin, LGALS8 (galectin 8) can inhibit cell adhesion and induce apoptosis by binding to integrin a4αβ3 to modulate cell-matrix interactions [39], Therefore, high level of APEH and LGALS8 is beneficial to patient survival. CBR1 (carbonyl reductase 1) may reduce the effect of many anti-cancer drugs by metabolization, such as reducing the effect of doxorubicin in breast cancer patients [40] and attenuating the effect of arsenic trioxide in leukemia patients [41]. Thus, low level of CBR1 (CNV) is linked to better prognosis. In summary, this shared subnetwork implied that low activity of ubiquitin/proteasome degradation by low presence of UBA5/UFM1, and effective removal of oxidatively damaged proteins by APEH are linked to better prognosis.

iref2/multinet1

RAB6A is a member of RAS oncogene family localized at Golgi apparatus [42], and RABGAP1 is a RAB6A activating protein playing a role in the coordination of microtubule and Golgi dynamics during the cell cycle [43]. CHML (CHM like, Rab escort protein 2) inhibits the geranylgeranylation reaction on RABs [44] and TMF1 (TATA element modulatory factor 1) is a conserved Golgi protein that binds to RAB6 and influences Golgi morphology [45], depletion of which blocks membrane transport among endosome, Golgi and ER [46]. Downregulation of TMF has been shown in solid tumors while overexpression of TMF significantly attenuated the growth of xenograft tumors [47]. Therefore, our prediction that low RAB oncogenic activity of by low CNV_RAB6A and mRNA_RABGAP1 and high level of their inhibitory factors CHML (mRNA, CNV) and CNV_TMF1 are beneficial for patient survival agrees well with previous studies.

Meanwhile, we would like to raise the point that one should carefully interpret and apply our results, because they are based on prognosis, which is from an outcome angle rather than from a causal angle. For example, we identified quite large amount of subnetworks that low ubiquitin/proteasome degradation is linked to better prognosis, which agrees well with current view of inhibiting ubiquitin/proteasome pathway proved to be effective strategies to treat various malignancies [48]. However, it does not necessarily mean that inhibiting ubiquitin/proteasome pathway will inhibit tumor growth, because there is still a possibility that low ubiquitin/proteasome activity is very likely an outcome of efficient ubiquitin/proteasome dependent mechanism to degrade oncogenic proteins (i.e. oncogenic products, oxidatively damaged proteins). It is also quite controversial about whether ER stress and UPR lead to cancer cell survival or death, which are context-dependent [49]. Thus, though our subnetworks biomarkers are quite efficient to predict TNBC patient outcome, one should carefully apply them when developing therapeutic strategies to specifically activate or inhibit members in the subnetworks.

Furthermore, we would like to advance the importance of integrating/combining multiple data types. Previous studies mainly focused on analyzing individual data type. Here, we found different data types from 66 and 376 genes significantly associated with TNBC and non-TNBC survival respectively. The major contribution of the 66 genes in TNBC came from DNA methylation (35 out of 66), while the contribution from both mRNA and CNV come from 16 genes. Such a difference may explain why combined molecular data type has a better prediction (highest C-index) than individual molecule data type (Figure (Figure5).5). In contrast, 199 mRNA, 34 CNV, and 147 DNA methylation significantly associated with survival in non-TNBC, which also explained why mRNA was the best to predict survival for non-TNBC (highest C-index in Figure Figure55).

Additionally, it should be noted that our study still has some limitations that could guide future work. First, our predictive quality largely depends on the data itself and data quality we used. TCGA is the most comprehensive dataset available to us, but TNBC patients are quite limited and we had to leave miRNA information out because of insufficient samples left. Second, most of these TNBC patients are at early stage (stage I and II), and the lack of late stage TNBC patients (Stage III and IV) inevitably affects our final subnetworks. With more TNBC patients and the advancement of sequencing technology for various data types, our method could achieve better predictive results. Third, in statistical prediction, three other cross-validation methods (independent test, K-fold cross-validation, and jackknife test) are usually used to examine a predictor for its effectiveness in practical application and of the three test methods, the jackknife test is deemed the least arbitrary that can always yield a unique result for a given benchmark dataset [50]. Finally, as suggested by Chou [51], user-friendly and publicly accessible web-servers will significantly enhance the impacts in developing new prediction or analysis methods, thus we shall make efforts in our future work to provide a web-server for the identification method presented in here.

MATERIALS AND METHODS

Multi- dimensional genomic data

The multi-dimensional cancer-associated data sets containing clinical information, copy-number variation (CNV), promoter DNA methylation, mRNA expression were collected from TCGA Cancer Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). A brief summary of the data information is provided in Table Table1.1. TN was determined as negative of clinical calls for estrogen receptor (EsR), progesterone (PgR) and human epidermal growth factor receptor 2 (HER2), while non-TN was determined by at least one positive of the above receptors. In the end, we collected 119 samples for TNBC and 583 samples for non-TNBC, respectively.

Protein-protein interaction data

To date there is no single database of human protein-protein interactions with high sensitivity and specificity, yet we used three interaction networks with various types of interactions to allow for different false positive and false negative interactions described previously [22]. The data can be downloaded from:http://compbio-research.cs.brown.edu/pancancer/hotnet2/#!/data.

Basically, three networks were used: (1) HINT+HI2012, a combination of high-quality protein-protein interactomes from HINT [24] and HI-2012 [25] which consists of 40,783 interactions among 10,008 proteins; (2) iRefIndex [26], an integrated network from multiple data sources including various types of interactions (i.e. physical interaction, genetic inequality, (de)acetylation, (de)methylation, (de)phosphorylation, (de)ubiquitination) except for colocalizations and genetic interactions, which consists of 91,872 interactions among 12,338 proteins; and (3) MultiNet [27] a network that integrates multiple types of interactions, including protein-protein, phosphorylation, metabolic, signaling, genetic, and regulatory interactions from multiple databases, which consists of 109,597 interactions among 14,445 proteins.

Data filtering

CNV profiling was filtered with 12099 expressed genes described previously [22], which include 12,081 genes with at least 3 RNA-Seq reads per sample in at least 70% of samples from syn1734155 plus 18 well-known cancer genes. Finally, CNV of a total of 11878 genes was consolidated in 119 TNBC and 583 non-TNBC samples. The DNA methylation profile was measured experimentally using either the Illumina Infimum Human DNA Methylation 450K (433 samples) or 27K (287 samples) platform. After merging the data from the two platforms, 19847 probes were mapped to 13474 genes in 123 TNBC samples and 595 non-TNBC samples. The mRNA expression profile was filtered with the 12099 expressed genes and 11,442 genes were left. For TNBC and non-TNBC, we defined the sample intersection across all platforms as the core sample set.

Identification of novel survival-related subnetworks

Subnetwork signatures of survival-related genes were determined both by the scores of their genes, and the interactions among the genes. For each gene, we evaluated its effect on patient overall survival by taking into account the molecular features of mRNA expression, CNV, and promoter DNA methylation status. The R program “coxph” was used to fit a multivariate Cox proportional hazards model between each molecular feature and patient survival time adjusted for age, with the likelihood ratio test being used to estimate the significance. Only the features which passed the cutoff of p < 0.05 were considered to be survival-related. A heat score for each gene was calculated using the Equation (1) summarized as the sum negative natural logarithm of single survival-related molecular feature p-values, which is corresponded to Fisher's Method for combining p-values for (independent) statistical tests [23]. For DNA methylation, considering the fact that one gene may have multiple methylation loci, we only retained one CpG methylation probe that was most correlated with survival time.

score=2×mloge(pm),m=mRNA,CNV,methy
(1)

The genes with a score > 0 were identified as survival-related genes. Subnetwork signatures in individual PPI network were discovered using HotNet2 [22, 23], which uses a heat diffusion process with the gene heat score as the input and a statistical test based algorithm (Figure (Figure1A1A).

Ranking subnetworks based on their prognostic power

For each subnetwork, we firstly assembled a multi-dimensional molecular profile by extracting three types of molecular features of its gene members from the core sample set. We then explored the predictive power of the subnetwork on patient overall survival using a Monte Carlo cross-validation and permutation testing procedure. Briefly, for the core sample set, we randomly split the samples into two groups: 80% as the training set and 20% as the test set. For the training set, we used the Cox proportional hazards model with ElasticNet [52], a modified L1 penalized log partial likelihood (LASSO) [53] for feature selection to train the models based on the molecular profile of individual subnetwork. ElasticNet was used for feature selection, because it combines penalty terms of LASSO and Ridge to compromise variable selection and group effect, considering the potential intrinsic relations among biologically relevant genes and widespread co-linearity of large-scale biological data [52]. The prognostic outcomes for the training set were used to determine the regression coefficients. These coefficients were then used to predict outcomes for patients in the test set and calculate the C-index. The above procedure was repeated 100 times to generate 100 C-indexes and the median C-index was used as the predictive value for each subnetwork. C-index has been frequently applied to evaluate risk prediction model and survival analysis: A C-index of 1 indicates perfect prediction accuracy, while a C-index of 0.5 is equivalent to a random guess. Our survival predictive models were evaluated based on a research framework which could be accessed in Synapse (doi:10.7303/syn1710282) (Figure (Figure1B1B).

Selection of important molecular features for prognostic model building and tumor stratification

When building the predictive model using the molecular features of each subnetwork, ElasticNet was used to select a small number of “important” features. Basically, 100 samplings of the training set could extract 100 important feature sets and the occurrence of each molecular feature was counted. Since the possibility of random selection bias for any given feature could be ruled out if the feature was consistently selected for, we only kept features occurring more than 5 times to construct our final predictive model for each subnetwork-based biomarker. And all the selected molecular features derived from the 39 subnetwork models were used for tumor stratification.

Survival analysis

A risk score formula was established by weighting each of the selected features of the subnetwork by their estimated regression coefficients in the multivariable Cox regression analysis. With this risk score formula, we were able to calculate a subnetwork-based risk score (referred to as “snRS”) for each patient in the data set. Then the patients were classified into high-risk or low-risk groups using the median risk score as the cutoff. Survival differences between the low-risk and high-risk groups identified in each set were assessed by the Kaplan-Meier estimate and compared using the log-rank test. Univariate and multivariate analyses with Cox proportional hazards regression for overall survival were performed on the individual conventional clinical variables with and without the subnetwork-based signature in each dataset. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. All statistical tests were two-sided and performed with R software.

Assessment of the prognostic power of diverse or combined molecular features-based models

First, a pre-selection step to keep the top significant features correlated with overall survival (univariate Cox model, likelihood ratio test, p < 0.05) was performed as Yuan's study [20]. Next, the ElasticNet [52]+Cox was applied to train the models in training set. Then the trained predictive models were used to predict outcomes for patients in the test set for the C-index calculation. For TNBC or non-TNBC core set, the above procedure was repeated 100 times from the 100 times of randomly splitting of the core set into training and test sets to generate 100 prognostic models and the corresponding C-indexes. From the 100 prognostic models, only the models with a C-index > 0.5 and a permutation test p-value < 0.05 based on a 100 survival-permutated data were retained for downstream analysis (22 models for TNBC and 31 models for non-TNBC). In total,28 mRNA, 43 CNV, and 48 DNA methylation features mapping to 66 genes were selected from the 22 TNBC models. In contrast, 199 mRNA, 34 CNV, and 147 DNA methylation mapping to 376 genes were found significantly associated with survival from the 31 non-TNBC models.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Footnotes

CONFLICTS OF INTEREST

No potential conflicts of interest.

FUNDING

This research was supported by National Natural Science Foundation of China [31401127 to J.H. and 31200998 to F.Z].

REFERENCES

1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016 [PubMed]
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728. [PubMed]
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434. [PubMed]
4. Liedtke C, Rody A. New treatment strategies for patients with triple-negative breast cancer. Current opinion in obstetrics & gynecology. 2015;27:77–84. [PubMed]
5. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861. [PubMed]
6. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, et al. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. J Clin Oncol. 2012;30:2615–2623. [PMC free article] [PubMed]
7. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol. 2014;25:1122–1127. [PMC free article] [PubMed]
8. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32. [PubMed]
9. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clinical Cancer Research. 2008;14:1368–1376. [PubMed]
10. Zhou M, Zhong L, Xu W, Sun Y, Zhang Z, Zhao H, Yang L, Sun J. Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Sci Rep. 2016;6:31038. [PMC free article] [PubMed]
11. Cheng L, Jiang Y, Wang Z, Shi H, Sun J, Yang H, Zhang S, Hu Y, Zhou M. DisSim: an online system for exploring significant similar diseases and exhibiting potential therapeutic drugs. Scientific reports. 2016;6:30024. [PMC free article] [PubMed]
12. Sun J, Shi H, Wang Z, Zhang C, Liu L, Wang L, He W, Hao D, Liu S, Zhou M. Inferring novel lncRNA-disease associations based on a random walk model of a lncRNA functional similarity network. Molecular bioSystems. 2014;10:2074–2081. [PubMed]
13. Zhou M, Wang X, Li J, Hao D, Wang Z, Shi H, Han L, Zhou H, Sun J. Prioritizing candidate disease-related long non-coding RNAs by walking on the heterogeneous lncRNA and disease network. Molecular bioSystems. 2015;11:760–769. [PubMed]
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. [PubMed]
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. [PubMed]
16. van de Vijver MJ, He YD, van ‘t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med. 2002;347:1999–2009. [PubMed]
17. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361:1590–1596. [PubMed]
18. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet. 2005;37:S31–S37. [PubMed]
19. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. [PubMed]
20. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature biotechnology. 2014;32:644–652. [PMC free article] [PubMed]
21. Zhang F, Ren C, Lau KK, Zheng Z, Lu G, Yi Z, Zhao Y, Su F, Zhang S, Zhang B, Sobie EA, Zhang W, Walsh MJ. A network medicine approach to build a comprehensive atlas for the prognosis of human cancer. Briefings in bioinformatics. 2016 [PubMed]
22. Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, Papoutsaki A, Kim Y, Niu B, McLellan M, Lawrence MS, Gonzalez-Perez A, Tamborero D, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature genetics. 2015;47:106–114. [PMC free article] [PubMed]
23. Vandin F, Clay P, Upfal E, Raphael BJ. Discovery of mutated subnetworks associated with clinical data in cancer. Pac Symp Biocomput. 2012:55–66. [PubMed]
24. Das J, Yu HY. HINT: High-quality protein interactomes and their applications in understanding human disease. Bmc Syst Biol. 2012:6. [PMC free article] [PubMed]
25. Yu HY, Tardivo L, Tam S, Weiner E, Gebreab F, Fan CY, Svrzikapa N, Hirozane-Kishikawa T, Rietman E, Yang XP, Sahalie J, Salehi-Ashtiani K, Hao T, et al. Next-generation sequencing to generate interactome datasets. Nat Methods. 2011;8:478–U2257. [PMC free article] [PubMed]
26. Razick S, Magklaras G, Donaldson IM. iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics. 2008;9:405. [PMC free article] [PubMed]
27. Khurana E, Fu Y, Chen JM, Gerstein M. Interpretation of Genomic Variants Using a Unified Biological Network Approach. Plos Comput Biol. 2013:9. [PMC free article] [PubMed]
28. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39:D52–D57. [PMC free article] [PubMed]
29. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics. 2013;14:128. [PMC free article] [PubMed]
30. Cancer Genome Atlas N Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. [PMC free article] [PubMed]
31. Sun J, Cheng L, Shi H, Zhang Z, Zhao H, Wang Z, Zhou M. A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. Sci Rep. 2016;6:27842. [PMC free article] [PubMed]
32. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. [PMC free article] [PubMed]
33. Zhang M, Zhu X, Zhang Y, Cai Y, Chen J, Sivaprakasam S, Gurav A, Pi W, Makala L, Wu J, Pace B, Tuan-Lo D, Ganapathy V, et al. RCAD/Ufl1, a Ufm1 E3 ligase, is essential for hematopoietic stem cell function and murine hematopoiesis. Cell Death Differ. 2015;22:1922–1934. [PMC free article] [PubMed]
34. Cai YF, Pi WH, Sivaprakasam S, Zhu XB, Zhang MS, Chen JJ, Makala L, Lu CW, Wu JC, Teng Y, Pace B, Tuan D, Singh N, et al. UFBP1, a Key Component of the Ufm1 Conjugation System, Is Essential for Ufmylation-Mediated Regulation of Erythroid Development. Plos Genet. 2015:11. [PMC free article] [PubMed]
35. Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, Ka SH, Sou YS, Komatsu M, Tanaka K, Lee ST, Noh DY, Baek SH, et al. Modification of ASC1 by UFM1 Is Crucial for ER alpha Transactivation and Breast Cancer Development. Mol Cell. 2014;56:261–274. [PubMed]
36. Fujino T, Watanabe K, Beppu M, Kikugawa K, Yasuda H. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase. Bba-Protein Struct M. 2000;1478:102–112. [PubMed]
37. Naylor SL, Marshall A, Hensel C, Martinez PF, Holley B, Sakaguchi AY. The Dnf15s2 Locus at 3p21 Is Transcribed in Normal Lung and Small Cell Lung-Cancer. Genomics. 1989;4:355–361. [PubMed]
38. Erlandsson R, Bergerheim USR, Boldog F, Marcsek Z, Kunimi K, Lin BYT, Ingvarsson S, Castresana JS, Lee WH, Lee E, Klein G, Sumegi J. A Gene near the D3f15s2 Site on 3p Is Expressed in Normal Human Kidney but Not or Only at a Severely Reduced Level in 11 of 15 Primary Renal-Cell Carcinomas (Rcc) Oncogene. 1990;5:1207–1211. [PubMed]
39. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci. 2000;113:2385–2397. [PubMed]
40. Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD, Chowbay B. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:2045–2054. [PubMed]
41. Jang M, Kim Y, Won H, Lim S, Jyothi KR, Dashdorj A, Min YH, Kim SY, Shokat KM, Ha J, Kim SS. Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide. Cancer Res. 2012;72:4214–4224. [PubMed]
42. Opdam FJM, Echard A, Croes HJE, van den Hurk JAJM, van de Vorstenbosch RA, Ginsel LA, Goud B, Fransen JAM. The small GTPase Rab6B, a novel Rab6 subfamily member, is cell-type specifically expressed and localised to the Golgi apparatus. J Cell Sci. 2000;113:2725–2735. [PubMed]
43. Cuif MH, Possmayer F, Zander H, Bordes N, Jollivet F, Couedel-Courteille A, Janoueix-Lerosey I, Langsley G, Bornens M, Goud B. Characterization of GAPCenA, a GTPase activating protein for Rab6, part of which associates with the centrosome. Embo J. 1999;18:1772–1782. [PubMed]
44. Anant JS, Desnoyers L, Machius M, Demeler B, Hansen JC, Westover KD, Deisenhofer J, Seabra MC. Mechanism of Rab geranylgeranylation: formation of the catalytic ternary complex. Biochemistry. 1998;37:12559–12568. [PubMed]
45. Fridmann-Sirkis Y, Siniossoglou S, Pelham HR. TMF is a golgin that binds Rab6 and influences Golgi morphology. BMC Cell Biol. 2004;5:18. [PMC free article] [PubMed]
46. Yamane J, Kubo A, Nakayama K, Yuba-Kubo A, Katsuno T, Tsukita S, Tsukita S. Functional involvement of TMF/ARA160 in Rab6-dependent retrograde membrane traffic. Exp Cell Res. 2007;313:3472–3485. [PubMed]
47. Abrham G, Volpe M, Shpungin S, Nir U. TMF/ARA160 downregulates proangiogenic genes and attenuates the progression of PC3 xenografts. Int J Cancer. 2009;125:43–53. [PubMed]
48. Weathington NM, Mallampalli RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014;124:6–12. [PMC free article] [PubMed]
49. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14:581–597. [PubMed]
50. Chou KC. Some remarks on protein attribute prediction and pseudo amino acid composition. J Theor Biol. 2011;273:236–247. [PubMed]
51. Chou KC. Impacts of bioinformatics to medicinal chemistry. Med Chem. 2015;11:218–234. [PubMed]
52. Zou H, Hastie T. Regularization and variable selection via the elastic net. J Roy Stat Soc B. 2005;67:301–320.
53. Tibshirani RJ. Regression shrinkage and selection via the lasso. J Roy Stat Soc B. 1996;58:267–288.
54. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat. 2014;143:403–409. [PubMed]
55. Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29:1578–1586. [PubMed]
56. Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M, Lane L, Birnbaum D, Bertucci F. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. Plos One. 2011;6:e27656. [PMC free article] [PubMed]
57. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953–964. [PMC free article] [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC